Neurocrine Biosciences, Inc. (NBIX) EPS Estimated At $-0.32; Last Week Conn's, Inc. (CONN) Coverage

April 17, 2018 - By Dolores Ford

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Logo

Among 6 analysts covering CONN’S (NASDAQ:CONN), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. CONN’S had 20 analyst reports since August 17, 2015 according to SRatingsIntel. The rating was maintained by KeyBanc Capital Markets with “Buy” on Wednesday, October 18. Oppenheimer upgraded Conn's, Inc. (NASDAQ:CONN) on Friday, September 29 to “Outperform” rating. The stock of Conn's, Inc. (NASDAQ:CONN) has “Buy” rating given on Tuesday, October 24 by SunTrust. As per Thursday, September 7, the company rating was maintained by KeyBanc Capital Markets. KeyBanc Capital Markets maintained it with “Buy” rating and $4200 target in Friday, April 6 report. The company was upgraded on Wednesday, September 21 by Stifel Nicolaus. Piper Jaffray downgraded Conn's, Inc. (NASDAQ:CONN) on Friday, June 3 to “Neutral” rating. As per Tuesday, September 15, the company rating was downgraded by Stifel Nicolaus. The rating was upgraded by Stifel Nicolaus to “Buy” on Tuesday, December 1. Stephens upgraded the shares of CONN in report on Tuesday, March 15 to “Overweight” rating. See Conn's, Inc. (NASDAQ:CONN) latest ratings:

06/04/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $42.0000 Maintain
06/04/2018 Broker: Stephens Rating: Buy New Target: $42.0000 Maintain
14/12/2017 Broker: Stephens Rating: Buy New Target: $44.0
24/10/2017 Broker: SunTrust Rating: Buy New Target: $37.0 Maintain
18/10/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $42.0 Maintain

Analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report $-0.32 EPS on May, 8.They anticipate $0.58 EPS change or 64.44% from last quarter’s $-0.9 EPS. After having $0.07 EPS previously, Neurocrine Biosciences, Inc.’s analysts see -557.14% EPS growth. The stock increased 3.23% or $2.43 during the last trading session, reaching $77.73. About 613,285 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 91.92% since April 17, 2017 and is uptrending. It has outperformed by 80.37% the S&P500.

Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 54 analyst reports since August 18, 2015 according to SRatingsIntel. The firm has “Buy” rating by Oppenheimer given on Tuesday, March 13. The firm has “Buy” rating by Deutsche Bank given on Wednesday, February 14. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Thursday, February 22 by Needham. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Oppenheimer on Tuesday, December 12. The firm earned “Buy” rating on Thursday, November 2 by Oppenheimer. JP Morgan maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Wednesday, February 14 with “Overweight” rating. The company was maintained on Monday, January 8 by Piper Jaffray. Oppenheimer maintained the stock with “Buy” rating in Thursday, February 22 report. The company was maintained on Thursday, September 21 by Robert W. Baird. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Jefferies on Monday, June 26.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $6.99 billion. The company??s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women??s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson??s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Since January 2, 2018, it had 0 insider purchases, and 22 insider sales for $29.59 million activity. Gano Kyle had sold 1,625 shares worth $128,460. 9,500 shares were sold by RASTETTER WILLIAM H, worth $855,000 on Wednesday, January 24. Shares for $175,090 were sold by Lippoldt Darin. Grigoriadis Dimitri E. sold $6.76M worth of stock. GORMAN KEVIN CHARLES had sold 3,750 shares worth $295,820. On Monday, February 5 Lloyd-Smith Malcolm sold $79,863 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 960 shares. On Monday, February 5 the insider LYONS GARY A sold $415,380.

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.35, from 1.66 in 2017Q3. It worsened, as 18 investors sold Neurocrine Biosciences, Inc. shares while 76 reduced holdings. 58 funds opened positions while 65 raised stakes. 91.25 million shares or 1.56% less from 92.69 million shares in 2017Q3 were reported. Tudor Invest Et Al stated it has 28,868 shares. Btg Pactual Asset Mgmt Ltd holds 0.3% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 10,472 shares. Northwestern Mutual Wealth Mgmt Communication holds 96 shares. Parkside Savings Bank And Tru accumulated 140 shares. Great West Life Assurance Can holds 10,258 shares or 0% of its portfolio. Deutsche Savings Bank Ag accumulated 968,205 shares. Shanda Asset Mngmt Holdings invested 0.12% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Royal Bank Of Canada reported 7,922 shares stake. Mutual Of America Cap Mngmt Limited Liability Company, New York-based fund reported 107,653 shares. Loomis Sayles And Company Lp reported 114,779 shares. Bb Biotech Ag, a Switzerland-based fund reported 3.45 million shares. Columbus Circle Investors owns 318,806 shares. Advisory Research stated it has 7,167 shares or 0.01% of all its holdings. Glob X Mngmt Limited Company invested in 606 shares or 0% of the stock. Axa stated it has 147,710 shares.

Conn's, Inc. operates as a specialty retailer of durable consumer goods and related services in the United States. The company has market cap of $918.20 million. It operates through two divisions, Retail and Credit. It has a 145.5 P/E ratio. The companyÂ’s stores provide furniture and mattress, including furniture and related accessories for the living room, dining room, and bedroom, as well as traditional and specialty mattresses; home appliances comprising refrigerators, freezers, washers, dryers, dishwashers, and ranges; and home office products consisting of computers, printers, and accessories.

Since December 11, 2017, it had 3 insider purchases, and 1 insider sale for $54.10 million activity. On Tuesday, April 10 the insider Bchara George L bought $202,524. Schofman David bought $32,198 worth of stock or 1,000 shares. Shares for $142,128 were bought by Daly Brian. 1.60 million Conn's, Inc. (NASDAQ:CONN) shares with value of $54.48M were sold by Anchorage Capital Group – L.L.C..

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>